It has been shown that activation of KRAS-MAPK cascade can lead to the phosphorylation of ERα, which will in turn activate the transcriptional activity of the target genes of ERα and enable BC cells to gain survival advantages and bypass tamoxifen therapy-induced inhibition [18]. Here, KRAS is linked to breast cancer.